The glacial development of Fate’s anti-CD19 Car-NK therapy FT596 could yield real data at last.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
Nantkwest claims efficacy with its most advanced NK cell therapy but, as ever with Patrick Soon-Shiong companies, it’s complicated.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
With many of the usual targets on display Fate, Celyad, Allovir and others look to maintain momentum.
Sanofi goes all in on Kiadis's natural killer cell projects, gained through an all-stock deal in 2019.
Drug developers raised a record $4.5bn in IPOs in the third quarter, and investor support for biopharma shows little sign of waning.